Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Atezolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention. Browse Atezolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
512
Shown on this page
12
Current sort
Recently updated
Therapy scope
Atezolizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Atezolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 265–276 of 512 matching trials for Atezolizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Results available

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT03738228
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
Interventions
Atezolizumab, Brachytherapy, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

NCT03371017
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Results available

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

NCT03468426
View directory record Official record
Conditions
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
Interventions
BI 836880, Ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Terminated Phase 2 Interventional Results available

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT04373369
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Vorolanib, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT02599454
View directory record Official record
Conditions
Stage I Non-Small Cell Lung Cancer
Interventions
Atezolizumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Sacramento, California • Travis AFB, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Active, not recruiting Phase 3 Interventional

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

NCT05468489
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Withdrawn Phase 2 Interventional

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

NCT06557278
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
AlloStim, Bavencio
Biological · Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Miami Beach, Florida • Brooklyn, New York • Shirley, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

NCT04631029
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Atezolizumab, Carboplatin, Entinostat, Etoposide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
New York, New York • Pittsburgh, Pennsylvania • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 30, 2026, 5:08 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

NCT06784947
View directory record Official record
Conditions
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 5:08 AM EDT

About this Atezolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Atezolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Atezolizumab.